Is there a diabetes pill that works better than oral semaglutide?
Yes. In this 52-week phase 3 trial, the once-daily pill orforglipron lowered HbA1c more than oral semaglutide in adults with type 2 diabetes. At the top dose, it cut HbA1c by 1.91% from a baseline of 8.3%, compared with 1.47% for semaglutide 14 mg.
For years, the strongest GLP-1 drugs came as weekly shots. Oral semaglutide changed that by putting a GLP-1 medicine into a daily tablet. This trial, called ACHIEVE-3, tested whether a different kind of pill could do the same job with fewer rules and better results.
How the new pill works
Orforglipron is a non-peptide GLP-1 receptor agonist. In plain terms, it copies a natural gut hormone that tells your body you are full and helps control blood sugar after meals. GLP-1 drugs like semaglutide do the same thing, but they are large, peptide-based molecules that your gut breaks down easily. That is why most need injections.
Because orforglipron is a small chemical rather than a peptide, it was designed for daily oral dosing without food or water restrictions. That is a real practical difference, since dosing rules can be hard to follow every single day.
What the data show
The trial enrolled 1,698 adults with type 2 diabetes whose blood sugar was not well controlled on metformin at 1,500 mg per day or more, with HbA1c between 7.0% and 10.5% and a BMI of at least 25. They were randomly assigned to orforglipron 12 mg or 36 mg, or oral semaglutide 7 mg or 14 mg, and treated for 52 weeks at 131 centers in Argentina, China, Japan, Mexico, and the USA.
Starting from a baseline HbA1c of 8.3%, the mean drops at week 52 were 1.71% with orforglipron 12 mg, 1.91% with orforglipron 36 mg, 1.23% with semaglutide 7 mg, and 1.47% with semaglutide 14 mg. Orforglipron 36 mg beat semaglutide 14 mg by 0.44% (95% CI 0.26 to 0.62, p<0.0001), and orforglipron 12 mg beat semaglutide 7 mg by 0.48% (0.31 to 0.65, p<0.0001). The low orforglipron dose also beat the high semaglutide dose, by 0.24% (0.072 to 0.41, p=0.0050). Non-inferiority was the primary goal, and both orforglipron doses cleared it and then showed superiority to both semaglutide doses.
The main downside was gastrointestinal side effects. These hit 59% of the orforglipron 12 mg group and 58% of the 36 mg group, versus 37% on semaglutide 7 mg and 45% on semaglutide 14 mg, and most were mild to moderate. More people stopped treatment because of adverse events on orforglipron, 9% on 12 mg and 10% on 36 mg, than on semaglutide, 4% on 7 mg and 5% on 14 mg. Mean pulse rate rose more on orforglipron, by 3.7 bpm on 12 mg and 4.7 bpm on 36 mg, versus 1.0 and 1.5 bpm on semaglutide. Four deaths occurred during the study: one in each orforglipron group and two on semaglutide 7 mg.
Dr. Kumar’s Take
This pill did not just match oral semaglutide, it beat it on blood sugar, and even the low orforglipron dose beat the high semaglutide dose. For a patient, a drug designed to be taken with or without food is a big deal, because the medicine only works if people actually take it consistently.
I do want to keep this in perspective. This was an open-label trial, meaning both patients and doctors knew which drug was being used, and that can nudge results. Fifty-two weeks is a solid look but not a long-term one, and hard outcomes like heart attacks or strokes prevented are not available yet. The tolerability gap is real: more gastrointestinal trouble, more people quitting because of side effects, and a larger rise in resting pulse than with semaglutide. How the dose is raised will matter in practice, and the pulse increase is worth watching in anyone with existing heart disease. The trial was funded by Eli Lilly.
Study snapshot
ACHIEVE-3 was a multinational, multicenter, open-label, randomized phase 3 trial designed to test non-inferiority, meaning the first goal was simply to show orforglipron was not worse than oral semaglutide, using a margin of 0.3% for HbA1c. It went further and showed the pill was better on the main measure. Participants were adults with type 2 diabetes still above target on metformin, a very common real-world starting point. Recruitment ran from September 2023 to August 2025. The head-to-head design is what makes this useful, because it compares the new pill against a strong oral option that is already available, not against a placebo.
Who benefits most
The people most likely to gain here are those who need better blood sugar control but want to avoid injections. A pill designed without food and water timing rules also helps anyone who has struggled to follow a strict dosing schedule. People who are especially sensitive to nausea may need a slower dose increase to stay comfortable, since gastrointestinal events and dropouts were both more common on orforglipron.
Practical Takeaways
- If you take metformin but your blood sugar is still high, ask your doctor whether a GLP-1 pill could be a next step for you.
- Gastrointestinal side effects were the most common problem and were more frequent with orforglipron than with oral semaglutide, so ask about a slower dose increase if they bother you.
- Ask your doctor about your heart rate on this drug, since mean pulse rose more on orforglipron than on semaglutide.
- Do not stop or switch any diabetes medicine on your own, since these drugs were studied under medical supervision and dosing matters.
Related Studies and Research
- A weekly shot for type 2 diabetes that also drops 14% of body weight
- New pill cuts LDL cholesterol by 57% in major trial
- Creatine for type 2 diabetes: a placebo-controlled trial
- A randomized controlled trial of mindfulness-based cognitive therapy for major depressive disorder in undergraduate students
FAQs
Is orforglipron the same thing as semaglutide?
No. Orforglipron is a non-peptide chemical that works on the same GLP-1 receptor, and it was designed for daily oral administration without food or water restrictions. Semaglutide is a peptide drug, and this trial tested it in its oral form.
How much did the new pill lower blood sugar?
Starting from a baseline HbA1c of 8.3%, orforglipron 36 mg lowered it by 1.91% at 52 weeks and orforglipron 12 mg lowered it by 1.71%. Oral semaglutide lowered it by 1.47% at 14 mg and 1.23% at 7 mg. Every orforglipron comparison came out ahead, including the 12 mg dose against semaglutide 14 mg.
What are the main side effects to expect?
The most common problems were gastrointestinal, reported by 59% of people on orforglipron 12 mg and 58% on 36 mg, compared with 37% and 45% on semaglutide 7 mg and 14 mg. Most were mild to moderate rather than severe. About 1 in 10 people on orforglipron stopped treatment because of adverse events, roughly twice the rate seen with semaglutide. Anyone who has ongoing or severe symptoms should talk with their doctor about adjusting the plan.
Bottom Line
In a head-to-head phase 3 trial of 1,698 adults with type 2 diabetes on metformin, the once-daily pill orforglipron beat oral semaglutide on blood sugar, cutting HbA1c by 1.91% at the 36 mg dose versus 1.47% for semaglutide 14 mg, from a baseline of 8.3%. It was designed to be taken without food or water restrictions, at the cost of more gastrointestinal side effects, more discontinuations, and a larger rise in pulse rate. If longer trials confirm these gains and show real heart benefits, this could become a leading oral option for type 2 diabetes.
